UNSPSC 51352212: Hexestrol dipropionate

This classification denotes a non-steroidal estrogen C24H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 87WC4ICV8O, chemically known as phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, 1,1'-dipropanoate, but more generally known as hexestrol dipropionate, which bears US NIH Compound Identifier 107342. Most nations, for tariff and trade purposes, schedule hexestrol dipropionate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIPROPIONATE remains US FDA's Preferred Term for this commodity.

SMILES: CC[C@H](C1CCC(CC1)OC(=O)CC)[C@@H](CC)C2CCC(CC2)OC(=O)CC.

UNSPSC 51352212 Hexestrol dipropionate is a Commodity code representing individual pharmaceutical products supplied to state and local healthcare facilities through multi-state cooperative purchasing frameworks. State and local governments procure this and related generic pharmaceuticals primarily via cooperative agreements that aggregate demand across participating jurisdictions, leveraging volume to negotiate competitive pricing and ensure reliable supply chains. The typical solicitation requires vendors to maintain relationships with authorized drug wholesalers, comply with FDA cGMP and Drug Supply Chain Security Act requirements, provide detailed product specifications including National Drug Codes and packaging configurations, and offer flexible pricing structures such as flat price, net price formats, or WAC-minus arrangements. Issuing bodies include state health departments and purchasing offices administering multistate cooperative purchasing alliances that serve state agencies, local governments, and healthcare institutions across multiple states.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with an effective date of July 1, 2026 and response deadline of March 26, 2026. The procurement spans participating state and local facilities including Oregon, with awarded vendors required to distribute through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation emphasizes price competitiveness (75 percent weight), with the remainder weighted across fixed pricing terms, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security liability of $2,000,000, and professional liability of $2,000,000, and contracts are awarded for two-year terms with optional extensions at MMCAP's discretion.